Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lexapro Prescribers: Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 7, 2007
Google's (Nasdaq:GOOG) Mastery of the Personal Medical Record Will be HUGE
Analysis of: Google Aims to Extend Data Mantra into Health Care | www.eweek.com
Author: GLG Expert Contributor
Google never ceases to amaze.  In the present era of disruptive technologies, Google is on the verge of another (extremely positive) venture into storage and accessibility of personal medical information.  Consider all the implications this will have.
June 7, 2007
Retail Clinics: A Disruptive Event, But a Boon to Patients
Analysis of: Retail clinics: Accepting the inevitable | www.fiercehealthcare.com
Author: GLG Expert Contributor
Like all disruptive events, the emergence of retail clinics will be met with fierce resistance by the primary care physician community.  However, ultimately the consumer will be a winner, for a number of reasons.
June 7, 2007
Cipralex (Lexapro) Trumps Duloxetine - or Does it?
Analysis of: Newly Published Data Shows Superiority Of Cipralex® Over Duloxetine For Acute Treatment Of Depression | www.medicalnewstoday.com
Author: GLG Expert Contributor
A new study purports to show that Cipralex (Lexapro...escitalopram) is more effective vs. Duloxetine in the short-term treatment of depression.  This study may be blurring important distinctions betwen these two medications, that are important in clinical practice.
June 6, 2007
Aspire Implant May Lead to Re-Education of Some Sleepy Patients.
Analysis of: Aspire Medical Announces First Implant In US And Start Of Clinical Trial To Treat Sleep Apnea | www.medicalnewstoday.com
Author: GLG Expert Contributor
If Aspire's tongue implant device for Obstructive Sleep Apnea (OSA) makes it to market, and I believe it probably will, this will mandate the re-education of many sleepy patients, who sleep at all the wrong times.
June 6, 2007
Avanir's New Clozaril Formulation (12.5mg in bottles!) -- A Big Yawn?
Analysis of: Avanir Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo | pharmalive.com
Author: GLG Expert Contributor
Avanir's new FazaClo formulation (12.5mg in bottles!) may represent a small gain in convenience, but its launch will hardly be exciting.  There are several reasons it will add little to market share for FazaClo.
June 6, 2007
Evotec AG Scores a Technical Knockout in Sleep Arena...Here's Why
Analysis of: Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201 | www.pipelinereview.com
Author: GLG Expert Contributor
Evotec's EVT 201 shows stellar results in a phase II clinical trial and the drug has several features which could make this a technical knockout...for a huge number of chronic insomniacs.
June 4, 2007
Shire (SHPGY) Builds An Empire That Will Be Difficult to Topple
Analysis of: Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting | www.shire.com
Author: GLG Expert Contributor
Shire is rapidly amassing an empire in the important market for ADD/ADHD pharmaceuticals.  Its latest offerings further strengthen its dominance.
June 4, 2007
Aspire Implant May Take A Bite Out of Sleep Med Market
Analysis of: Aspire Medical Announces First Implant In US And Start Of Clinical Trial To Treat Sleep Apnea | www.medicalnewstoday.com
Author: GLG Expert Contributor
Aspire has a very promising new approach to OSA (Obstructive Sleep Apnea).  This will have implications for sleep medications.
June 4, 2007
Invasive Devices for Depression Not Catching On
Analysis of: Support Wavers for Brain Stimulation | www.clinicalpsychiatrynews.com
Author: GLG Expert Contributor
=== Vagal Nerve Stimulators (VNS) from companies like Cyberonics [CYBX] haven't captured as much of the market as once hoped for.   === Deep Brain Stimulation (DBS), from companies like Medtronic [MDT], is losing steam as mentioned in this article.   === Transcranial Magnetic Stimulation (TMS),...
June 4, 2007
FazaClo Announcement a Yawner
Analysis of: Avanir Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo | pharmalive.com
Author: GLG Expert Contributor
• Clozapine (Clozaril, FazaClo) is the original atypical antipsychotic used to treat schizophrenia and some bipolar disorders. Usual daily dose is 300-500 mg. • Adding a 12.5 mg dose adds little to the management... breaking a 25 mg tab in half is pretty easy to do. • Blister packs...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next91 to 100 of 157

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440